Single application thixotropic antibiotic delivery systems for otitis externa

项目总结 外耳感染(外耳炎或OE)在一生中影响大约10%的人，与 医疗保健费用每年超过5亿美元。这种病理在一般情况下是可以治疗的。 使用局部抗生素制度的人群，并可在严重情况下与全身对应人员进行补充。 然而，抗生素的错误使用或不遵守给药程序会导致感染。 抗生素耐药菌株的持久性、复发性和潜在的发展。在糖尿病或老年人中 患者，感染可能危及生命，因为它可以发展为坏死性或恶性外耳炎(MOE)， 会造成严重的健康后果。近年来，MOE的发病率呈显著上升趋势。 并与抗药性细菌菌株有关。因此，迫切需要发展 安全有效的治疗OE和预防MOE的方法。我们解决这个问题的方法是 开发ThixOtic，这是一种专有药物输送系统，将使一次性护理点 应用药物有效治疗感染，降低治疗不依从相关风险 抗生素耐药性的产生、感染复发和并发症。

PROJECT SUMMARY Outer ear infections (otitis externa or OE) affect an estimated 10% of people in their lifetime, with associated healthcare costs amounting to over $500 million annually. The pathology is mostly treatable in the general population with topical antibiotics regimes, and can be supplemented in severe cases with systemic counterparts. However, incorrect application or non-compliance with administration schedule of antibiotics leads to infection persistence, recurrence and potentially, development of antibiotic resistant bacterial strains. In diabetic or elderly patients, the infection can be life threatening as it can progress into necrotizing or malignant otitis externa (MOE), with severe health consequences. In recent years, the incidence rate of MOE has seen a significant increase and has been associated with antibiotic resistant bacterial strains. Therefore, there is a critical need to develop safe and effective therapies for the treatment of OE and prevention of MOE. Our approach to this problem is the development of ThixOtic, a proprietary drug delivery system that would enable the one-time point-of-care application of drugs to effectively treat the infection and diminish treatment non-compliance related risk of antibiotic resistance development, infection recurrence and complications.